Oculis Holding AG
OCSAWDrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
licaminlimab
Dry Eye Disease (DED)
Dexamethasone ophthalmic suspension (OCS-01)
Diabetic Macular Edema
OCS-01
Uveitis Related Cystoid Macular Edema
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
licaminlimab | Phase 3 | Dry Eye Disease (DED) | - | - |
Dexamethasone ophthalmic suspension (OCS-01) | Phase 3 | Diabetic Macular Edema | - | - |
OCS-01 | Phase 2 | Uveitis Related Cystoid Macular Edema | - | - |
Frequently asked questions
What is in Oculis Holding AG's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Oculis Holding AG's (OCSAW) pipeline across Phase 3, Phase 2. Its lead program is licaminlimab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Oculis Holding AG's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Oculis Holding AG (OCSAW) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track OCSAW biotech catalysts?→
Add OCSAW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Oculis Holding AG's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.